Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Melanoma 3Kidney Neoplasms 3Head and Neck Neoplasms 3Uterine Cervical Neoplasms 2Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Lung Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Thyroid Neoplasms 1Soft Tissue Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1

Interventions

Mitoxantrone 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Androgen-independent Prostate Cancer × Cetuximab × Genitourinary × Clear all
NCT00661492 2016-12-09

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

US Oncology Research

Phase 2 Completed
115 enrolled 16 charts
Genitourinary

Androgen-independent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡